Serological evidence that activation of ubiquitous human herpesvirus-6 (HHV-6) plays a role in chronic idiopathic/spontaneous urticaria (CIU)
| Autor: | David H. Dreyfus |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male 0301 basic medicine Herpesvirus 4 Human Urticaria Herpesvirus 6 Human viruses Immunology Omalizumab Antibodies Viral medicine.disease_cause Herpesviridae Virus Autoimmune Diseases Serology 030207 dermatology & venereal diseases 03 medical and health sciences Herpesviridae Infections 0302 clinical medicine Virus latency medicine Humans Immunology and Allergy biology business.industry Original Articles Middle Aged medicine.disease biology.organism_classification Virus Latency 030104 developmental biology Drug Hypersensitivity Syndrome Female Virus Activation Human herpesvirus 6 business medicine.drug |
| Zdroj: | Clinical and Experimental Immunology. 183:230-238 |
| ISSN: | 1365-2249 0009-9104 |
| Popis: | Summary Acute infection with viral pathogens in the herpesviridae family can trigger acute urticaria, and reactivation of herpesviridae is associated with cutaneous urticarial-like syndromes such as drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DRESS). Reactivation of latent herpesviridae has not been studied systematically in chronic idiopathic/spontaneous urticaria (CIU). This review proposes that CIU is an inflammatory disorder with autoimmune features (termed ‘CVU’ for chronic viral urticaria), based on serology consistent with the hypothesis that reactivation of a latent herpesvirus or -viruses may play a role in CIU. Serology obtained from a cohort of omalizumab (Xolair)-dependent patients with severe CIU was consistent with previous HHV-6 infection, persistent viral gene expression and replication. CIU patients also exhibited serological evidence of increased immune response to HHV-4 (Epstein–Barr virus, or EBV) but not all CIU patients were infected with EBV. These observations, combined with case reports of CIU response to anti-viral therapy, suggest that HHV-6, possibly interacting with HHV-4 in cutaneous tissues, is a candidate for further prospective study as a co-factor in CIU. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text